Quick Takeaways
- Carl L. Gordon has 11 issuer positions tracked on this page.
- Estimated disclosed ownership value: $33,638,698.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Carl L. Gordon
- Location
- New York, NY
- Summary
- The estimated net worth of Carl L. Gordon is at least $33,638,698 dollars as of 05 Jan 2026. Carl L. Gordon is the Director of Venetian-1 Acquisition Corp. and owns shares of Lomond Therapeutics Holdings, Inc. stock worth about $10.71M. Carl L. Gordon is the Director, 10%+ Owner of MBX Biosciences, Inc. and owns shares of MBX Biosciences, Inc. (MBX) stock worth about $8.11M. Carl L. Gordon is the Director, 10%+ Owner of Terns Pharmaceuticals, Inc. and owns shares of Terns Pharmaceuticals, Inc. (TERN) stock worth about $7.56M. Carl L. Gordon is the Director, 10%+ Owner of ArriVent Biopharma, Inc. and owns shares of ArriVent BioPharma, Inc. (AVBP) stock worth about $5.52M. Carl L. Gordon is the Director, 10%+ Owner of Adicet Bio, Inc. and owns shares of Adicet Bio, Inc. (ACET) stock worth about $941.6K. Carl L. Gordon is the Director of Keros Therapeutics, Inc. and owns shares of Keros Therapeutics, Inc. (KROS) stock worth about $799.8K.
- Signature
- /s/ Neil Lerner, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Carl L. Gordon and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Venetian-1 Acquisition Corp. ($10,709,024).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Carl L. Gordon
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| Venetian-1 Acquisition Corp. | Director | $10,709,024 | 01 Nov 2024 | |||
| MBX | MBX Biosciences, Inc. | Director, 10%+ Owner | $8,107,095 | 14 Feb 2025 | ||
| TERN | Terns Pharmaceuticals, Inc. | Director, 10%+ Owner | $7,556,350 | 15 Jul 2024 | ||
| AVBP | ArriVent Biopharma, Inc. | Director, 10%+ Owner | $5,524,874 | 30 Jan 2024 | ||
| ACET | Adicet Bio, Inc. | Director, 10%+ Owner | $941,594 | 21 Aug 2024 | ||
| KROS | Keros Therapeutics, Inc. | Director | $799,761 | 21 Nov 2025 | ||
| CMPX | Compass Therapeutics, Inc. | Director | $0 | -$5,678,571 | -100% | 02 Jan 2026 |
| KNTE | Kinnate Biopharma Inc. | Director, 10%+ Owner | $0 | 03 Apr 2024 | ||
| THRX | Theseus Pharmaceuticals, Inc. | Director, 10%+ Owner | $0 | 14 Feb 2024 | ||
| IRON | Gemini Therapeutics, Inc. /DE | Director, 10%+ Owner | 04 Oct 2021 | |||
| ORIC | Oric Pharmaceuticals, Inc. | Director, 10%+ Owner | 16 Jun 2021 |
Insider Transactions Reported by Carl L. Gordon:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.